Heterogeneous nuclear ribonucleoprotein K is overexpressed and contributes to radioresistance irrespective of HPV status in head and neck squamous cell carcinoma.


Journal

International journal of molecular medicine
ISSN: 1791-244X
Titre abrégé: Int J Mol Med
Pays: Greece
ID NLM: 9810955

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 07 05 2020
accepted: 17 08 2020
pubmed: 10 9 2020
medline: 1 7 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Radiotherapy is a major treatment option for head and neck squamous cell carcinoma (HNSCC). However, the success of radiotherapy is limited by tumor cell resistance to ionizing radiation (IR). Clinical studies have demonstrated an overall improved prognosis and higher susceptibility to radiotherapy of high‑risk human papillomavirus (HPV)‑associated HNSCC compared with classic HNSCC, as well as worse overall survival for male HNSCC patients. Overexpression of heterogeneous nuclear ribonucleoprotein (hnRNP) K has been associated with resistance to radiotherapy in melanoma and colorectal carcinoma. The aim of the present study was to analyze the impact of hnRNP K expression on the aggressiveness and radioresistance of HNSCC with respect to patient sex and HPV status. Immunohistochemical staining of HNSCC tissue specimens revealed elevated hnRNP K levels compared with those in the non‑neoplastic epithelium. Cytoplasmic hnRNP K accumulation was associated with advanced tumor stage and male sex. Exposure of HNSCC cells to IR was followed by rapid upregulation of hnRNP K at the protein level, along with re‑localization from the tumor cell nucleus to the cytoplasm. siRNA‑based knockdown of hnRNP K induced apoptosis and abolished tumor formation after xenotransplantation of HNSCC cells onto the chick egg chorioallantoic membrane (CAM). The observed effects were independent of the respective HPV status of the cell lines. These results indicated a tumorigenic and anti‑apoptotic role of hnRNP K in HNSCC, which appeared to be enhanced in male patients and contributed to the radioresistance of these tumors. However, the radioprotective effects of hnRNP K were found to be independent of the tumor's HPV status.

Identifiants

pubmed: 32901844
doi: 10.3892/ijmm.2020.4718
pmc: PMC7521550
doi:

Substances chimiques

Heterogeneous-Nuclear Ribonucleoprotein K 0
RNA, Small Interfering 0
HNRNPK protein, human 146410-60-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1733-1742

Références

Virchows Arch. 2014 Aug;465(2):155-63
pubmed: 24915895
J Biol Chem. 2013 May 24;288(21):15046-56
pubmed: 23564449
Cancer Lett. 2017 Jan 28;385:160-167
pubmed: 27793696
Cancer Res. 1990 Oct 15;50(20):6502-7
pubmed: 2208109
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Sci Rep. 2016 Mar 14;6:22999
pubmed: 26972480
Cell. 2005 Dec 16;123(6):1065-78
pubmed: 16360036
Int J Radiat Biol. 2009 Aug;85(8):643-55
pubmed: 19579069
J Cell Mol Med. 2017 Jul;21(7):1266-1279
pubmed: 27862976
Bioessays. 2004 Jun;26(6):629-38
pubmed: 15170860
PLoS One. 2011 Mar 25;6(3):e18148
pubmed: 21464958
Nucleic Acids Res. 2014 Sep;42(15):9908-24
pubmed: 25104022
Carcinogenesis. 2017 Mar 1;38(3):321-328
pubmed: 28426877
PLoS One. 2016 Mar 10;11(3):e0151098
pubmed: 26963717
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Adv Sci (Weinh). 2018 Jun 14;5(8):1701036
pubmed: 30128225
Int J Cancer. 2009 Sep 15;125(6):1398-406
pubmed: 19548310
Am J Physiol Renal Physiol. 2007 Aug;293(2):F607-15
pubmed: 17581920
Semin Radiat Oncol. 2012 Apr;22(2):128-42
pubmed: 22385920
Cell Death Differ. 2010 Sep;17(9):1463-73
pubmed: 20224598
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Clin Cancer Res. 2013 May 1;19(9):2486-92
pubmed: 23532894
Cell Cycle. 2016 Jun 17;15(12):1552-7
pubmed: 27049467
Cell Signal. 2008 May;20(5):969-77
pubmed: 18295448
Oral Oncol. 2012 Jun;48(6):516-22
pubmed: 22321252
Cancer. 2017 May 1;123(9):1566-1575
pubmed: 28241096
Sci Rep. 2017 May 03;7:46690
pubmed: 28466861
Head Neck Pathol. 2012 Jul;6 Suppl 1:S16-24
pubmed: 22782220
BMC Cancer. 2014 May 20;14:348
pubmed: 24885469
Oncotarget. 2015 Jul 10;6(19):17178-91
pubmed: 26136337
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Br J Cancer. 2007 Aug 20;97(4):574-5; author reply 576
pubmed: 17667925
Cancer Lett. 2014 Oct 1;352(2):152-9
pubmed: 25016060
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Br J Cancer. 2006 Oct 9;95(7):921-7
pubmed: 16953238
J Proteomics. 2015 Jan 15;113:154-61
pubmed: 25281771
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59
pubmed: 30241572
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731

Auteurs

Justus Kähler (J)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Susanne Hafner (S)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, D‑89081 Ulm, Germany.

Tanja Popp (T)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Cornelius Hermann (C)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Alexis Rump (A)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Matthias Port (M)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Konrad Steinestel (K)

Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, D‑89081 Ulm, Germany.

Stefan Eder (S)

Bundeswehr Institute of Radiobiology, D‑80937 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH